CCEGF: AI 评分 46/100 — AI 分析 (4月 2026)

Carclo plc specializes in fine tolerance injection molded plastic parts, serving the medical, aerospace, and electronics industries. The company operates globally, with a focus on technical plastics and aerospace components.

Key Facts: AI Score: 46/100 Sector: Consumer Cyclical

公司概况

概要：

Carclo plc, established in 1924, manufactures fine tolerance injection molded plastic components across medical, aerospace, and electronics sectors. With a global presence spanning the UK, North America, and Asia, Carclo leverages its technical plastics and aerospace divisions to serve diverse industrial needs, maintaining a modest profit margin within the consumer cyclical industry.

CCEGF是做什么的？

Carclo plc, founded in 1924 and based in Ossett, United Kingdom, specializes in the manufacture and sale of fine tolerance injection molded plastic parts. The company operates through three primary segments: Technical Plastics, Aerospace, and Central. The Technical Plastics division focuses on producing high-precision plastic components for the medical, optical, diagnostics, and electronics industries. These components are critical in devices requiring exacting specifications and reliability. The Aerospace division provides specialist components, including control cables, machined components, aerofoil blading, streamline wires, and tie rods, catering to both commercial and military aerospace applications. The Central segment supports the operational and strategic needs of the other two divisions. Carclo's global footprint extends across the United Kingdom, North America, the Czech Republic, China, and India, enabling it to serve a diverse international clientele. The company's products are essential in various applications, ranging from medical devices and diagnostic equipment to aircraft and electronic products. Carclo's commitment to precision and quality has established it as a key supplier in its niche markets. The company's long history and specialized expertise provide a competitive edge in the fine tolerance plastics and aerospace components industries.

CCEGF的投资论点是什么？

Carclo plc presents a mixed investment thesis. The company's specialization in fine tolerance injection molded plastic parts for critical industries like medical and aerospace provides a degree of resilience. The Aerospace division, in particular, offers potential for stable, long-term contracts. However, the company's relatively small market capitalization ($0.05B) and modest profit margin (1.6%) suggest vulnerability to economic downturns and competitive pressures. A P/E ratio of 19.09 indicates that the stock is trading at a premium compared to its earnings. Key value drivers include the ability to secure and maintain contracts in the aerospace sector and the successful development of new applications for its technical plastics. Investors should closely monitor the company's ability to improve profitability and manage its cost structure. The absence of a dividend may deter some investors seeking regular income.

CCEGF在哪个行业运营？

Carclo plc operates within the auto parts industry, a segment of the broader consumer cyclical sector. This industry is influenced by trends in automotive manufacturing, aerospace, and medical device production. The competitive landscape includes companies specializing in precision components and plastic molding. Carclo differentiates itself through its focus on fine tolerance injection molding and its presence in both the technical plastics and aerospace markets. The industry is subject to fluctuations in demand based on economic cycles and technological advancements. Carclo's ability to adapt to changing market conditions and maintain its technological edge is crucial for its long-term success.

Auto - Parts

Consumer Cyclical

CCEGF有哪些增长机遇？

Expansion in the medical device market: The increasing demand for sophisticated medical devices presents a significant growth opportunity for Carclo's Technical Plastics division. As medical technology advances, the need for high-precision plastic components will continue to rise. Carclo can leverage its expertise in fine tolerance injection molding to capture a larger share of this market. The global medical device market is projected to reach $600 billion by 2028, providing a substantial runway for growth. Timeline: Ongoing.
Increased demand in the aerospace sector: The aerospace industry is experiencing a resurgence, driven by increased air travel and defense spending. Carclo's Aerospace division is well-positioned to benefit from this trend. The company's ability to provide specialist components for both commercial and military aircraft creates a stable and growing revenue stream. The global aerospace market is expected to grow at a rate of 4-5% annually over the next decade. Timeline: Ongoing.
Geographic expansion in Asia: The Asian market, particularly China and India, offers significant growth potential for Carclo. These regions are experiencing rapid economic growth and increasing demand for high-quality plastic components and aerospace parts. Carclo can expand its presence in Asia through strategic partnerships and investments in local manufacturing facilities. This expansion can diversify its revenue base and reduce its reliance on mature markets. Timeline: 2-3 years.
Development of new materials and technologies: Investing in research and development to create new materials and technologies can provide Carclo with a competitive edge. This includes exploring advanced polymers and molding techniques that can improve the performance and durability of its products. By staying at the forefront of technological innovation, Carclo can attract new customers and expand its market share. Timeline: Ongoing.
Strategic acquisitions: Carclo can pursue strategic acquisitions to expand its product portfolio and geographic reach. This includes acquiring companies with complementary technologies or access to new markets. Acquisitions can accelerate Carclo's growth and enhance its competitive position. Careful due diligence and integration are essential for successful acquisitions. Timeline: 3-5 years.

Market capitalization of $0.05B reflects its small-cap status within the consumer cyclical sector.
P/E ratio of 19.09 suggests the stock is trading at a premium relative to its earnings.
Profit margin of 1.6% indicates relatively low profitability, requiring close monitoring of cost management.
Gross margin of 56.8% demonstrates strong pricing power in its niche markets.
Beta of 0.70 suggests lower volatility compared to the overall market.

CCEGF提供哪些产品和服务？

Manufactures fine tolerance injection molded plastic parts.
Supplies components for the medical, optical, diagnostics, and electronics industries.
Provides specialist components for the commercial and military aerospace industries.
Offers control cables, machined components, aerofoil blading, streamline wires, and tie rods.
Operates in the United Kingdom, North America, the Czech Republic, China, and India.
Focuses on high-precision plastic components and aerospace parts.

CCEGF如何赚钱？

Manufacturing and selling fine tolerance injection molded plastic parts.
Providing specialist components to the aerospace industry.
Generating revenue through long-term contracts and project-based sales.
Operating through three segments: Technical Plastics, Aerospace, and Central.

Medical device manufacturers.
Aerospace companies (both commercial and military).
Electronics manufacturers.
Optical and diagnostics equipment producers.

Specialized expertise in fine tolerance injection molding.
Long-standing relationships with key customers in the medical and aerospace industries.
Global presence with manufacturing facilities in multiple countries.
Proprietary technologies and processes for producing high-precision components.

什么因素可能推动CCEGF股价上涨？

Ongoing: Increased demand for medical devices requiring high-precision plastic components.
Ongoing: Resurgence in the aerospace industry driving demand for specialist components.
Upcoming: Potential strategic acquisitions to expand product portfolio and geographic reach.
Ongoing: Investment in research and development to create new materials and technologies.
Ongoing: Geographic expansion in Asia to tap into high-growth markets.

CCEGF的主要风险是什么？

Potential: Economic downturns impacting demand in cyclical industries.
Ongoing: Increased competition from other manufacturers of plastic components.
Potential: Fluctuations in raw material prices affecting profit margins.
Potential: Technological obsolescence requiring continuous innovation.
Ongoing: Limited liquidity and higher volatility due to OTC market listing.

CCEGF的核心优势是什么？

Specialized expertise in fine tolerance injection molding.
Strong presence in the aerospace industry.
Global manufacturing footprint.
Long-standing customer relationships.

CCEGF的劣势是什么？

Small market capitalization.
Low profit margin.
Dependence on cyclical industries.
Limited brand recognition.

CCEGF有哪些机遇？

Expansion in the medical device market.
Growth in emerging markets.
Development of new materials and technologies.
Strategic acquisitions.

CCEGF面临哪些威胁？

Economic downturns.
Increased competition.
Fluctuations in raw material prices.
Technological obsolescence.

CCEGF的竞争对手是谁？

Can-Technologies Co., Ltd. — Focus on automotive components. — (CTTMF)
Enmech Co Ltd — Specializes in precision engineering. — (ENMHF)
Huf Hülsbeck & Fürst GmbH & Co. KG — Automotive locking systems and components. — (HFUS)
Inflexion Acquisition Corp — Focus on special purpose acquisitions. — (IFLXF)
Lear Corporation — Automotive seating and electrical systems. — (LEAT)

Key Metrics

MoonshotScore: 46/100

Company Profile

CEO: Franciscus Lodewijk Paulus Doorenbosch
Headquarters: Mitcham, GB
Employees: 1,059
Founded: 2012

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Carclo plc do?

Carclo plc specializes in the manufacture and sale of fine tolerance injection molded plastic parts, serving the medical, aerospace, and electronics industries. The company operates through three segments: Technical Plastics, Aerospace, and Central. The Technical Plastics division focuses on high-precision components for medical devices and diagnostic equipment, while the Aerospace division provides specialist components for commercial and military aircraft. Carclo's business model involves generating revenue through long-term contracts and project-based sales, leveraging its specialized expertise and global manufacturing footprint.

What do analysts say about CCEGF stock?

As of 2026-03-16, formal analyst ratings for CCEGF are limited due to its OTC listing and smaller market capitalization. However, key valuation metrics include a P/E ratio of 19.09 and a profit margin of 1.6%. Growth considerations revolve around the company's ability to capitalize on opportunities in the medical device and aerospace markets, as well as its success in expanding its geographic presence. Investors should closely monitor the company's financial performance and its ability to manage costs and maintain its competitive edge. The absence of a dividend may impact its appeal to income-seeking investors.

What are the main risks for CCEGF?

The main risks for Carclo plc include its exposure to cyclical industries, such as automotive and aerospace, which are sensitive to economic downturns. Increased competition from other manufacturers of plastic components and fluctuations in raw material prices can also negatively impact the company's profitability. Additionally, the company faces the risk of technological obsolescence, requiring continuous investment in research and development. Its OTC listing presents risks related to limited liquidity and higher volatility, potentially making it more difficult to trade the stock.